We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Modular, Cost-Efficient System Accelerates Traditional AST Turnaround Times by Up To One Day

By LabMedica International staff writers
Posted on 13 Jun 2023
Print article
Image: The eQUANT system has been submitted to FDA for 510(k) clearance (Photo courtesy of Avails Medical)
Image: The eQUANT system has been submitted to FDA for 510(k) clearance (Photo courtesy of Avails Medical)

The rising global prevalence of superbugs and increasing antimicrobial resistance pose a significant public health threat. Rapid diagnostics in clinical laboratories can play a crucial role in tackling this pressing issue. Now, a new system for the rapid detection and quantification of pathogens leverages digital biosensors that react to the small metabolic byproducts generated by microorganisms, allowing for growth detection and precise pathogen quantification. The system can empower physicians to shift from expensive empiric, broad-spectrum antibiotics to a more affordable, effective treatment, becoming a real game changer for patients.

The eQUANT system from Avails Medical (Menlo Park, CA, USA) offers a standardized inoculum (equivalent to 0.5 McFarland) directly from a positive blood culture. Designed to work in tandem with traditional automated antibiotic susceptibility testing (AST) systems and disk diffusion, it accelerates routine AST turnaround times by approximately a day. The eQUANT system, based on a compact single-module instrument, incorporates a cuvette equipped with an electrical sensor that is inoculated with a diluted sample of positive blood culture. It continuously monitors the changes in the metabolic byproducts of microorganisms in real-time, providing accurate, organism-specific 0.5 McFarland suspensions that are compatible with standard AST methods, including disk diffusion.

The eQUANT system offers a small footprint, user-friendly interface, and cost-effectiveness, making it suitable for widespread adoption. It has been engineered to maximize benchtop space in the clinical laboratory, accommodating the use of single or multiple units for processing all positive blood cultures in small to large microbiology labs. A pilot study conducted earlier at two internationally recognized clinical laboratories demonstrated a >98% correlation between the eQUANT system and the subculture gold standard. Avails Medical has submitted the eQUANT system for FDA 510(k) clearance.

"We are delighted to announce the important company milestone of FDA submission of the highly anticipated eQUANT system"' said Dr. Knopfmacher, CEO of Avails Medical. "This is an important first step towards commercializing eQUANT in the U.S. and other countries. eQUANT can provide any clinical laboratory with a simple and powerful tool that is designed to fit seamlessly into the routine clinical laboratory's workflow, accelerating traditional AST turnaround times by up to one day."

Related Links:
Avails Medical 

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.